Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Rosedale, NY
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Rosedale, NY
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Columbus, OH
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Bethlehem, PA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Sumter, SC
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Sumter, SC
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Chattanooga, TN
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Houston, TX
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Seattle, WA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Spokane, WA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Wenatchee, WA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated:  3/15/2014
Clinical Research Facility
mi
from
Lakewood, CO
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated: 3/15/2014
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated:  3/15/2014
Clinical Research Facility
mi
from
Miami, FL
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated: 3/15/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated:  3/15/2014
Clinical Research Facility
mi
from
Orlando, FL
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated: 3/15/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated:  3/15/2014
Clinical Research Facility
mi
from
Minneapolis, MN
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated: 3/15/2014
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated:  3/15/2014
Clinical Research Facility
mi
from
Saint Paul, MN
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease
Status: Enrolling
Updated: 3/15/2014
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated:  3/25/2014
Clinical Research Facility
mi
from
Miami, FL
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated: 3/25/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated:  3/25/2014
Clinical Research Facility
mi
from
Orlando, FL
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated: 3/25/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated:  3/25/2014
Clinical Research Facility
mi
from
St. Paul, MN
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated: 3/25/2014
Clinical Research Facility
mi
from
St. Paul, MN
Click here to add this to my saved trials
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated:  3/25/2014
Clinical Research Facility
mi
from
San Antonio, TX
Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Status: Enrolling
Updated: 3/25/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects
Status: Enrolling
Updated:  3/25/2014
Clinical Research Facility
mi
from
Orlando, FL
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects
Status: Enrolling
Updated: 3/25/2014
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
Mechanisms of CKD-Induced Foam Cell Formation
Status: Enrolling
Updated:  3/26/2014
Vanderbilt Outpatient Dialysis Center
mi
from
Nashville, TN
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
Mechanisms of CKD-Induced Foam Cell Formation
Status: Enrolling
Updated: 3/26/2014
Vanderbilt Outpatient Dialysis Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Observational Study of Blood Pressure Measurements and Continuous Dialysis
Observational Study Evaluating the Hemodynamic Relationship Between Volume Removal and Pulse Pressure Variation During Renal Replacement Therapy
Status: Enrolling
Updated:  3/27/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Observational Study of Blood Pressure Measurements and Continuous Dialysis
Observational Study Evaluating the Hemodynamic Relationship Between Volume Removal and Pulse Pressure Variation During Renal Replacement Therapy
Status: Enrolling
Updated: 3/27/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)
A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease
Status: Enrolling
Updated:  4/4/2014
Clinical Research Facility
mi
from
Coronado, CA
Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)
A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease
Status: Enrolling
Updated: 4/4/2014
Clinical Research Facility
mi
from
Coronado, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)
A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease
Status: Enrolling
Updated:  4/4/2014
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)
A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease
Status: Enrolling
Updated: 4/4/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Effects of Sevelamer Carbonate on Diabetic Nephropathy
Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy
Status: Enrolling
Updated:  4/8/2014
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
The Effects of Sevelamer Carbonate on Diabetic Nephropathy
Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy
Status: Enrolling
Updated: 4/8/2014
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
The Effects of Sevelamer Carbonate on Diabetic Nephropathy
Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy
Status: Enrolling
Updated:  4/8/2014
Beth Israel Med Ctr
mi
from
New York, NY
The Effects of Sevelamer Carbonate on Diabetic Nephropathy
Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy
Status: Enrolling
Updated: 4/8/2014
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Boceprevir in End Stage Renal Disease (ESRD)
Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic Hepatitis C (HCV) With End Stage Renal Disease (ESRD)
Status: Enrolling
Updated:  4/10/2014
Columbia University Medical Center - NYPH
mi
from
New York, NY
Boceprevir in End Stage Renal Disease (ESRD)
Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic Hepatitis C (HCV) With End Stage Renal Disease (ESRD)
Status: Enrolling
Updated: 4/10/2014
Columbia University Medical Center - NYPH
mi
from
New York, NY
Click here to add this to my saved trials
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated:  4/16/2014
Pediatric Nephrology of Alabama
mi
from
Birmingham, AL
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated: 4/16/2014
Pediatric Nephrology of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated:  4/16/2014
UCLA
mi
from
Los Angeles, CA
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated: 4/16/2014
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated:  4/16/2014
Stanford University
mi
from
Stanford, CA
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated: 4/16/2014
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated:  4/16/2014
Emory University
mi
from
Atlanta, GA
Calcineurin Inhibitor Based Immunosuppression Withdrawal
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression
Status: Enrolling
Updated: 4/16/2014
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation
Status: Enrolling
Updated:  5/19/2014
University of Miami
mi
from
Miami, FL
Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation
Status: Enrolling
Updated: 5/19/2014
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease (KXK005).
Status: Enrolling
Updated:  5/20/2014
University of Virginia Health System
mi
from
Charlottesville, VA
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease (KXK005).
Status: Enrolling
Updated: 5/20/2014
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
University of California, San Diego
mi
from
San Diego, CA
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
Rady Children's Hospital
mi
from
San Diego, CA
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
University of Colorado
mi
from
Aurora, CO
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
University of Michigan
mi
from
Ann Arbor, MI
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
St. Peter's Hospital
mi
from
Albany, NY
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
St. Peter's Hospital
mi
from
Albany, NY
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
Jacobi Medical Center
mi
from
New York, NY
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
Jacobi Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated:  6/5/2014
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
The Drug Induced Renal Injury Consortium
The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)
Status: Enrolling
Updated: 6/5/2014
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
All Children's Hospital of South Florida
mi
from
Tampa, FL
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
All Children's Hospital of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
Children's Hospital - Boston
mi
from
Boston, MA
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
Children's Hospital Oakland
mi
from
Oakland, CA
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
Children's Mercy Hospital
mi
from
Kansas City, MO
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
Cohen Children's Medical Center of NY
mi
from
New Hyde Park, NY
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
Cohen Children's Medical Center of NY
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated:  6/19/2014
Columbia University Medical Center
mi
from
New York, NY
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology
Status: Enrolling
Updated: 6/19/2014
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials